Increasing vaccine potency through exosome antigen targeting

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Classical cancer vaccine approaches targeting tumor-associated antigens (TAAs) have shown limited efficacy.
• Exosomes are known to traffic to antigen-presenting cells (APCs), suggesting potential for enhanced immunogenicity.
• A method exists to target proteins to exosomes using the C1C2 domain of lactadherin.

Purpose of the Study:

• To investigate if targeting TAAs to exosomes can increase their immunogenicity.
• To evaluate the therapeutic anti-tumor effects of exosome-targeted TAAs.

Main Methods:

• Adenoviral vectors were engineered to express the extracellular domain (ECD) of carcinoembryonic antigen (CEA) and HER2, fused to the C1C2 lactadherin domain.
• Expression of C1C2 fusion proteins in exosomes was analyzed in vitro.
• Antigen-specific immune responses and therapeutic anti-tumor effects were assessed in transgenic animal models.

Main Results:

• C1C2 fusion proteins demonstrated enhanced expression in exosomes.
• Significant improvements in antigen-specific immune responses were observed in both naïve and tolerant animal models.
• Markedly enhanced therapeutic anti-tumor effects were achieved in a HER2+ transgenic animal model.

Conclusions:

• Exosomal targeting of TAAs can significantly enhance immunogenicity and anti-tumor efficacy.
• The mode of protein secretion and trafficking influences TAA immunogenicity, potentially explaining the ineffectiveness of non-mutated TAAs in cancer vaccines.
• Exosome targeting represents a promising strategy for future anti-cancer vaccination protocols and may be applicable to other vaccine development challenges.